- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 23.03. | Apogee strengthens case for longer-lasting eczema drug | ||
| 23.03. | Pfizer, Valneva to seek approval of Lyme disease vaccine despite mixed study results | ||
| 23.03. | FDA seeks feedback on voucher program; Study data lift 'overhang' on Insmed shares | ||
| 23.03. | Risk, readiness and resilience | ||
| 20.03. | Earendil Labs, an AI-powered drugmaker, hauls in $787M | ||
| 20.03. | Roche stops work on experimental SMA drug | ||
| 20.03. | Novartis pays $2B to land a startup's breast cancer drug | ||
| 20.03. | Rhythm obesity drug wins broader use from FDA | ||
| 19.03. | Novo uses FDA voucher to win speedy approval of higher-dose Wegovy | ||
| 19.03. | Lilly's three-pronged obesity drug hits goal in large diabetes trial | ||
| 19.03. | Pfizer aims for wider use of PARP drug in prostate cancer with new data | ||
| 19.03. | A biotech VC sees early signs of a turnaround for startups | ||
| 19.03. | AstraZeneca to boost cell therapy capabilities with new China investment | ||
| 18.03. | RBC: Revolution, Xenon, Arrowhead among top takeover targets | ||
| 18.03. | J&J wins FDA nod for psoriasis pill that aims to compete with top-selling injections | ||
| 18.03. | Aspen's fresh Parkinson's data; Aldeyra tanks following FDA rejection | ||
| 18.03. | Crossbow raises $77M for new cancer immunotherapies | ||
| 18.03. | Chinese biotech startup Excalipoint banks $69M for next-gen T cell engagers | ||
| 17.03. | Bicycle to lay off 30% of staff, pivot away from Padcev challenger | ||
| 17.03. | Pfizer's Ibrance successor moves forward with new study data | ||
| 17.03. | Federal court blocks RFK Jr.'s moves to upend US vaccine policy | ||
| 17.03. | R1 starts up with $78M, aiming for a better kidney drug | ||
| 16.03. | CytomX surges on positive data for 'masked' ADC in colorectal cancer | ||
| 16.03. | Structure's GLP-1 pill shows 'best-in-class' potential in obesity trial | ||
| 16.03. | Sarepta tests new Elevidys safeguards; Sana advances diabetes cell therapy |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.